Literature DB >> 11915735

[Chemotherapy for small-cell lung cancer (SCLC) patients with renal failure].

Takashi Obana1, Yoshiro Tanio, Masahiko Takenaka, Dai Watanabe, Masahiko Yanagita, Sumihiro Nakajima, Keiko Okuda, Yoshiharu Tsubakihara, Hiroaki Fushimi.   

Abstract

We administered chemotherapy in three cases of small-cell lung cancer (SCLC) with renal failure under different situations. Hemodialysis (HD) was used in 2 out of the 3 cases. Case 1 was complicated by acute renal failure from extensive bilateral tumor invasion. After chemotherapy (CBDCA + ETP) under HD, renal metastases regressed and renal function improved, although the final response was PD. In case 2, HD had been introduced for diabetic nephropathy. After 2 cycles of chemotherapy (CBDCA + ETP) under HD, the patient attained a PR. Case 3 is an example of paraneoplastic nephrotic syndrome with renal failure. Chemotherapy including CBDCA or CDDP was performed and the QOL of the patient improved. Pro-GRP and serum creatinine changed in parallel during the clinical course of 6 admissions. In conclusion, individualized therapy is necessary to increase survival time of SCLC patients with renal failure. Although chemotherapy is useful, further study is needed for the selection of suitable chemotherapeutic regimens, optimal dosage of each drug and the timing of HD.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11915735

Source DB:  PubMed          Journal:  Gan To Kagaku Ryoho        ISSN: 0385-0684


  1 in total

Review 1.  Effect of haemodialysis on the pharmacokinetics of antineoplastic drugs.

Authors:  Masatoshi Tomita; Yoichi Aoki; Kenichi Tanaka
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.